JAK2 and myeloproliferative disorder: In murine models, momelotinib is unable to completely eliminate JAK2-dependent cells, and MPN often reappears, suggesting that it is not curative and is better used in combinational therapy.451 In clinical studies, Momelotinib is effective in treating MF patients at a dosage of 200 mg twice a day or 300 mg once daily.